08.26.25 -- Find Top Small Molecule CDMOs With Available Capacity For Adapted Solutions

PCI is positioned to meet the future of sterile pharmaceutical development and manufacturing with technology and solutions for high-value biologics, complex formulations, and lyophilized drug products.

Novartis Contract Manufacturing introduces their fill and finish solutions and capacity. Explore an overview of the aseptic network of Novartis and the capabilities of each site.

Gain an overview of a new state-of-the-art Groninger filling line’s capabilities, production scale-up timelines, and how this new infrastructure supports product flexibility and long-term growth for partners.

INCOG's balanced framework addresses the unique challenges of sterile manufacturing by integrating risk-based decision making with systematic capacity planning.

Applications specialist John Stevens shows how MilliporeSigma is using their 35+ years of CDMO experience and expertise to move customers’ small molecules forward to the clinic and beyond to commercialization.

ASDs are an attractive option for progressing and commercializing poorly soluble compounds. Find capabilities to screen the potential for ASDs in early phase studies and their commercial applicability.

With capabilities to support your next small molecule drug substance program from R&D to commercial scale, learn about integrated facilities, project teams, and available capacity.

Explore specialized expertise in solving challenging small molecule formulation problems (poor solubility, bioavailability, complex delivery routes).

Ian Lafferty, CTO, and Josh Moule, Business Development Manager, talk through Upperton’s capabilities, project management approach and provide a virtual tour of their 60,000 sq. ft development and manufacturing facility.

Dr. Rebecca Coutts highlights PCI’s high potent oral solid dose (OSD) and oral liquid capabilities, focusing on site expertise, specialized infrastructure, and handling of complex molecules.

Bora Pharmaceuticals specializes in formulation development, clinical and commercial manufacturing, and packaging of complex oral solid dose, liquid, semi-solid, and sterile injectable products.

Compressed timelines pose challenges, ranging from limited API supply to clinical trial logistics. Explore how expedited review pathways can be strategically used to accelerate development while mitigating CMC risks.

Lora Wallis and Chris Cuthbertson highlight Douglas CDMO’s strengths in high-potency softgels and liquids and the company's 67 years of expertise and a client-centric approach.

Pedro Morales, Director, Scientific Advisor of Biologics Analytical Services, explores how Catalent delivers tailored solutions through deep expertise and advanced capabilities.

Explore real examples of how KBI Biopharma has supported its partners through transparency that empowers, integration that simplifies, methods that de-risk, and experience that accelerates.

Alcami’s laboratory services can support many drug substance or drug product modalities, all product phases, and specialty laboratory services, including in-house microbiology, raw materials, and analytical development.

ReciBioPharm’s specialized CDMO capabilities include development and manufacture for new biological modalities. Choose a CDMO with complete end-to-end services and in-house analytical capabilities.

With more than 65 years of sterile injectable manufacturing experience, Simtra offers world-class GMP sterile fill and finish services, deep scientific and technical expertise, and a uniquely collaborative approach.

Leveraging Lonza's deep ADC expertise and experience, successfully develop high quality, commercially viable processes, spanning from pre-clinical development through commercial scale manufacturing.

With more than 15 years of experience as conjugation and linker-payload CDMO, MilliporeSigma has a proven track record of supporting clinical programs from IND to PPQ for commercialization.